Frans Wuite has more than 25 years pharmaceutical industry experience encompassing leadership roles in start-ups through to large, international companies. Prior to joining Acesion, Wuite led Oncos Therapeutics, a clinical stage cancer immunotherapy company which was successfully merged with Targovax in 2015. At Oncos he spearheaded fund raising and business development initiatives in the US and Europe. Wuite also pioneered the commercial development and launch of Amgen's anaemia therapy, Aranesp in Europe, which rapidly became the company's biggest product. He also gained early stage clinical development experience at Warren & Araim Pharmaceuticals in the US. Wuite is a board director of Healthcap VII GP S.A. and Herantis Pharma Ltd
Pharmaceutical